NATIONAL COMMUNITY PHARMACISTS ASSOCIATION for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Alcohol and Drug Abuse ALC
S. 2666, the E-Prescribing Parity for Controlled Substances Act; Remote Prescribing of Controlled Substances & Dispensing of Controlled Substances; H.R. 9886, the BUPE for Recovery Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN | — |
Medicare/Medicaid MMM
H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024 Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement; Comments to CMS on the implementation of Medicare Part D vaccine coverage under the Inflation Reduction Act (IRA; P.L. 117-169); Comments to CMMI on the Importance of Implementing Reasonable Reimbursement Guardrails for Pharmacies in the Medicare $2 Drug List Model based on the Executive Order on Lowering Prescription Drug Costs for Americans; Comments to HHS and CMS on 2024 NADAC Methodology Changes; Comment to CMS on "Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027."; H.R. 9096, the Pharmacists Fight Back Act; Long Term Care at Home Pharmacy Services in Medicare; Regulating fair and common-sense contracting guardrails between Part D plans/PBMs, and pharmacies; Comments to CMS on Proposed Rule Re: Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments [CMS-1807-P]; H.R.4758, the Accelerating Kids Access to Care Act; H.R. 8107, the Ensuring Access to Medicaid Buy-in Programs Act of 2024; Comments to CMS on Draft Guidance Re: Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN | — |
Pharmacy PHA
H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 2679, the Pharmacy Benefits Manager Accountability Act; H.R. 3008, the Drug Shortage Prevention Act; S. 1339, the Pharmacy Benefits Manager Reform Act; S. 1542 / H.R. 6283, the Delinking Revenue from Unfair Gouging Act; H.R. 1173, the Patients Right to Know Their Medication Act of 2023; Proposed rule for Medication Guides: Patient Medication Information (Docket No. FDA-2019-N-5959); Implementation of Public Law 113-54, the Drug Quality and Security Act; Draft Guidance for Industry, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act, (Docket No. FDA-2015-D-3517); H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act" (Docket No. FDA-2023-N-4806); Request for Information on Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024; H.R.2882, the Further Consolidated Appropriations Act, 2024; Comments on implementation and enforcement of recent changes to USP Chapter <797>, regarding the Compounded Sterile Preparations (CSPs) in Category 3 to the FDA; Comments to FDA on "Agency Information Collection Activities; Proposed Collection; Comment Request; Proposed Small Dispensers Assessment Under the Drug Supply Chain Security Act" [Docket No.FDA-2024-N-0668]; Comments to FDA on " Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act"[Docket No. FDA-2023-N-0061]; H.R.9096, the Pharmacists Fight Back Act; Comments to FDA on Docket No. FDA-2023-N-4806 - Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket; Request for Information and Comment.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN | — |
Taxation/Internal Revenue Code TAX
H.R. 4794, the Dietary Supplement Access Act; H.R.8147, Repealing Big Brother Overreach Act; H.R. 9278, To amend section 5336 of title 31, United States Code, to provide existing small businesses with an additional year to file beneficial ownership information, and for other purposes;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN | — |
Labor Issues/Antitrust/Workplace LBR
S. 127, the PBM Transparency Act; S. 113, the Prescription Pricing for the People Act; Request for Information on "Consolidation in Health Care Markets [Docket No. ATR 102]";
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN | — |
Defense DEF
TRICARE pharmacy network changes; H.R. 2670, National Defense Authorization Act for Fiscal Year 2024; H.R. 4638, National Defense Authorization Act for Fiscal Year 2025; S.4638, National Defense Authorization Act for Fiscal Year 2025;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN | — |
Budget/Appropriations BUD
FY24 appropriations language request to fund FTC enforcement of the Robinson-Patman Act; FY24 appropriations report language to address TRICARE pharmacy network; Labor, Health and Human Services, Education, and Related Agencies Appropriations Bill, FY 2025;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN | — |
Telecommunications TEC
Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.